CoChat

Uncovering the mode of action of engineered T cells in patient cancer organoids

Open access
Dekkers, Johanna F., Alieva, Maria, Cleven, Astrid, Keramati, Farid, Wezenaar, Amber K. L., van Vliet, Esmée J., Puschhof, Jens, Brazda, Peter, Johanna, Inez, Meringa, Angelo D., Rebel, Heggert G., Buchholz, Maj-Britt, Barrera Román, Mario, Zeeman, Amber L., de Blank, Sam, Fasci, Domenico, Geurts, Maarten H., Cornel, Annelisa M., Driehuis, Else, Millen, Rosemary, Straetemans, Trudy, Nicolasen, Mara J. T., Aarts-Riemens, Tineke, Ariese, Hendrikus C. R., Johnson, Hannah R., van Ineveld, Ravian L., Karaiskaki, Froso, Kopper, Oded, Bar-Ephraim, Yotam E., Kretzschmar, Kai, Eggermont, Alexander M. M., Nierkens, Stefan, Wehrens, Ellen J., Stunnenberg, Henk G., Clevers, Hans, Kuball, Jürgen, Sebestyen, Zsolt, Rios, Anne C. · 2023 · Nature Biotechnology
Cited by 227

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Extending the success of cellular immunotherapies against blood cancers to the realm of solid tumors will require improved in vitro models that reveal therapeutic modes of action at the molecular level. Here we describe a system, called BEHAV3D, developed to study the dynamic interactions of immune cells and patient cancer organoids by means of imaging and transcriptomics. We apply BEHAV3D to live-track >150,000 engineered T cells cultured with patient-derived, solid-tumor organoids, identifying a ‘super engager’ behavioral cluster comprising T cells with potent serial killing capacity. Among other T cell concepts we also study cancer metabolome-sensing engineered T cells (TEGs) and detect behavior-specific gene signatures that include a group of 27 genes with no previously described T cell function that are expressed by super engager killer TEGs. We further show that type I interferon can prime resistant organoids for TEG-mediated killing. BEHAV3D is a promising tool for the characterization of behavioral-phenotypic heterogeneity of cellular immunotherapies and may support the optimization of personalized solid-tumor-targeting cell therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41587-022-01397-w

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Metadata

Authors
Dekkers, J. F., Alieva, M., Cleven, A., Keramati, F., Wezenaar, A. K. L., van Vliet, E. J., Puschhof, J., Brazda, P., Johanna, I., Meringa, A. D., Rebel, H. G., Buchholz, M.-B., Barrera Román, M., Zeeman, A. L., de Blank, S., Fasci, D., Geurts, M. H., Cornel, A. M., Driehuis, E., Millen, R., Straetemans, T., Nicolasen, M. J. T., Aarts-Riemens, T., Ariese, H. C. R., Johnson, H. R., van Ineveld, R. L., Karaiskaki, F., Kopper, O., Bar-Ephraim, Y. E., Kretzschmar, K., Eggermont, A. M. M., Nierkens, S., Wehrens, E. J., Stunnenberg, H. G., Clevers, H., Kuball, J., Sebestyen, Z., & Rios, A. C.
Venue
Nature Biotechnology
Published
2022-07-25
Volume
41
Issue
1
Pages
60-69
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
OpenAlex
W4287510231
Cited by
227
References
28
FWCI
15.68
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Uncovering the mode of action of engineered T cells in patient cancer organoids. https://app.cochat.ai/papers/10.1038/s41587-022-01397-w
The paper
Dekkers, J. F., Alieva, M., Cleven, A., Keramati, F., Wezenaar, A. K. L., van Vliet, E. J., Puschhof, J., Brazda, P., Johanna, I., Meringa, A. D., Rebel, H. G., Buchholz, M.-B., Barrera Román, M., Zeeman, A. L., de Blank, S., Fasci, D., Geurts, M. H., Cornel, A. M., Driehuis, E., . . . Rios, A. C. (2023). Uncovering the mode of action of engineered T cells in patient cancer organoids. Nature Biotechnology. https://doi.org/10.1038/s41587-022-01397-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.